Breast Cancer Clinical Trial
— MACOfficial title:
Mindful After Cancer Study: Fostering Positive Body Image, Sexual Health, and Well-being
NCT number | NCT04559854 |
Other study ID # | 20181004 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2019 |
Est. completion date | October 5, 2020 |
Verified date | December 2020 |
Source | Oregon State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objectives of this study are to: 1) adapt a mindfulness-based therapy program designed to help women manage their sexual and body image concerns after cancer (Mindful After Cancer, MAC) to a videoconference format and 2) assess the feasibility, acceptability, and preliminary effects of the program among breast and gynecologic cancer survivors.
Status | Completed |
Enrollment | 28 |
Est. completion date | October 5, 2020 |
Est. primary completion date | October 1, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - Diagnosis of breast or gynecologic cancer at least one year prior to enrollment - English speaking - Have access to a computer, smart phone, or tablet with internet access - Ability to spend 15-30 minutes per day on program activities Exclusion Criteria: - Stage 0 (carcinoma in situ) |
Country | Name | City | State |
---|---|---|---|
United States | Oregon State University | Corvallis | Oregon |
Lead Sponsor | Collaborator |
---|---|
Oregon State University | OHSU Knight Cancer Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility/ Enrollment | Number of participants enrolled, Proportion of participants enrolled of those eligible | Baseline | |
Primary | Feasibility/ Retention in Study | Number and proportion of participants completing all assessments | 1 month post-intervention | |
Primary | Feasibility/ Retention in the Program | Mean number of sessions attended, Proportion of participants attending at least 6 of 8 sessions | 1 month post-intervention | |
Primary | Acceptability | Endorsement of 10 items characterizing acceptability (e.g., the program met my expectations). Range 10-100. Higher score indicates better acceptability. | 1 month post-intervention | |
Secondary | Change from baseline self-efficacy at 1 month | Self-efficacy for Managing Chronic Disease Scale (adapted). 6 items. Range 6-60. Higher score indicates better self-efficacy for managing sexual health after cancer. | Baseline and 1 month post-intervention | |
Secondary | Change from baseline body image at 1 month | Body Image Scale. 10 items. Range 0-30. Higher score indicates poorer body image. | Baseline and 1 month post-intervention | |
Secondary | Change from baseline body appreciation at 1 month | Body Appreciation Scale. 13 items. Range 13-65. Higher score indicates more positive body appreciation. | Baseline and 1 month post-intervention | |
Secondary | Change from baseline anxiety at 1 month | PROMIS Emotional Distress Anxiety Short Form 6a. 6 items. Range 6-30. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates greater anxiety symptoms. | Baseline and 1 month post-intervention | |
Secondary | Change from baseline depression at 1 month | Center for Epidemiologic Studies Depression Scale (CES-D). 20 items. Range 0-60. Higher score indicates greater depressive symptoms | Baseline and 1 month post-intervention | |
Secondary | Change in facets of baseline mindfulness at 1 month | Five-Facet Mindfulness Questionnaire (FFMQ-15). 15 items with 5 sub-scales: Observe, Describe; Act with Awareness; Non-Judgement, Non-Reactivity. Sub-scale score range 3-15. Higher score indicates greater mindfulness. | Baseline and 1 month post-intervention | |
Secondary | Change from baseline self-compassion at 1 month | Self-Compassion Scale short form. 12 items. Range 12-60. Higher score indicates greater self-compassion. | Baseline and 1 month post-intervention | |
Secondary | Change from baseline relationship quality at 1 month | Dyadic Adjustment Scale short form (DAS-7). Range 0-36. Higher score indicates more positive relationship quality | Baseline and 1 month post-intervention | |
Secondary | Change from baseline interest in sexual activity at 1 month | PROMIS SexFS 2.0. 2 items. Range 2-10. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates more interest in sexual activity. | Baseline and 1 month post-intervention | |
Secondary | Change from satisfaction with sex life at 1 month | New Sexual Satisfaction Scale- Short Form (NSSS-S). 12 items. Range 12-60. Higher score indicates more sexual satisfaction. | Baseline and 1 month post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |